Retatrutide
Three incretin receptors instead of two — the newest and, on trial data, the most effective compound in this category.
The most advanced weight loss peptide available: a triple agonist delivering superior fat reduction and metabolic control.
- Also known as
- LY3437943
- Class
- GIP, GLP-1 and glucagon receptor triple agonist
- Evidence
- Late-stage human trials
- FDA
- Not approved (investigational)
- WADA 2026
- Covered by S0: drugs still in clinical development are prohibited at all times
Concentrations · 1 vial
from R 1 75030mg selected — in stock and shipping now.
About Retatrutide
Retatrutide is a triple agonist: it acts on the GLP-1, GIP and glucagon receptors at once. Semaglutide works on one of those, tirzepatide on two, and the trial results have followed that progression — each additional receptor has produced larger effects on body weight than the generation before it. Retatrutide is the current end of that line and its phase 2 results were, by some margin, the largest seen in this class.
The glucagon receptor is what makes it structurally different from tirzepatide rather than simply stronger. Glucagon receptor agonism raises energy expenditure, which means Retatrutide is not only suppressing intake the way a pure GLP-1 does — it is acting on both sides of the balance. It is also the newest of the three, with correspondingly less long-term data behind it, which is a real consideration and not a marketing footnote.
Specifications
Evidence level: Late-stage human trials · Phase 3 results began appearing in 2026; not yet approved anywhere.
- Half-life
- About 6 days (phase 1b trial, Urva 2022)
Certificate of analysis
Independent lab test · Janoshik Analytical, 25 November 2025
- Report
- Task #90558
- Sample tested
- Retatrutide 30 mg, two vials, batch 2025.11
- Client on report
- ASK
- Method
- Identity, amount and peptide purity per vial
- Vial 1
- 30.52 mg · 99.892% purity
- Vial 2
- 29.14 mg · 99.931% purity
Results apply to the sample the lab tested. Check it at janoshik.com/verify with key CR8GTCWP7UQ9.
How our batches are tested
Demand for peptides has grown quickly, and the factories that make them now run batches far more often than they used to. When batches were large and infrequent, we could test each one ourselves. At today’s pace that stopped being practical: independent testing is priced per sample, per compound, in US dollars.
So we share it. STRIATA is one of a group of companies across South Africa that buy from the same factory, and together we split the cost of independent lab testing. Each test is paid for once and shared by everyone who buys from that factory, which lets the testing keep pace with the batches.
That is why the client named on a certificate may be another company, and why the vial in a lab’s photo may carry another brand’s label: the report names whoever sent that sample in. We publish every certificate exactly as the lab issued it, unedited. If you have a question about a certificate, ask us on WhatsApp.
What one test costs at Janoshik Analytical
- BPC-157 or TB-500US$215
- GHK-Cu, Semax, Selank or EpithalonUS$290
- Two-peptide blend (BPC-157/TB-500, CJC/Ipamorelin)US$320
- GLP-1 test (semaglutide, tirzepatide, retatrutide)US$360
- NAD+US$450
- KLOW four-peptide blendUS$800
- Endotoxin screen, added to any test+US$180
Per sample, from Janoshik’s published price list, checked 17 October 2026.
What it’s researched for
Research context, not medical advice. Everything we sell is supplied for research purposes.
Triple receptor agonism
GLP-1 for satiety and gastric emptying, GIP for insulin sensitivity, glucagon for energy expenditure — the three acting together is the whole design.
Body weight
The phase 2 results were the largest reported in this drug class, which is why Retatrutide commands the price it does despite being the least established.
Metabolic control
Studied for glycaemic endpoints alongside weight, consistent with the rest of the incretin class.
What the research does not show
The limits of the evidence, stated as plainly as the findings.
- Approval anywhere. It remains investigational.
- Long-term safety beyond the trial periods.
- Whether weight lost is maintained after stopping.
Reconstitution and storage
The 30mg vial reconstituted with 3 mL of bacteriostatic water gives 10mg/mL. The reconstitution calculator works out the concentration for whatever volume you choose. Unopened vials are stable at room temperature in transit but belong in a fridge once they arrive, and out of a parked car in a Highveld summer.
Questions we get about Retatrutide
Sources
- Urva S, Coskun T, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet, 2022.
- Jastreboff AM, Kaplan LM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 2023.
- Rosenstock J, Frias J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet, 2023.
- Bajaj HS, Welch M, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet, 2026.
- Giblin K, Kaplan LM, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity & Metabolism, 2026.
Often bought with it
Order Retatrutide in South Africa
Everything ships from Johannesburg, nationwide. Add it to your order slip, send the slip on WhatsApp, and we’ll confirm stock, pricing and delivery before you pay a cent.